immuno-oncology Nanobodies (Ablynx/Merck & Co)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameimmuno-oncology Nanobodies (Ablynx/Merck & Co)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionImmunomodulatorsCell cycle checkpoint pathway modulators
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAblynx Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck & Co IncAblynx Nv
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A